World

Home / World / Europe

CureVac fails in COVID-19 vaccine trial with 47% efficacy

By Ouyang Xueyan | chinadaily.com.cn | Updated: 2021-06-18 00:04

Share

Share - WeChat

German biotech CureVac's COVID-19 vaccine has come out of a late-stage trial with 47 percent efficacy but the health ministry has said this will not impact the country's vaccination rollout.

Photos

Federal workers feel squeeze for food during shutdown

Xi's message on openness resonates across L. America

China calls on Japan to match words with deeds after high-level meeting

Blueprint of inclusion praised as pragmatic

APEC expected to lead global green transition

APEC leaders jointly agree on AI vision

Most Viewed in 24 Hours

World in Focus

Fruitful friendship

Across Asia +

Cleaning up tallest rubbish tip

Deforestation in S.E. Asia causes more deaths than in other tropical areas

Special Coverage +

Live: Middle East truce stands amid claims of victory

Friends Afar +

Dive into the old world of Chinese martial arts

Ties That Bind +

Vital pass to boost China-Pakistan trade

BACK TO THE TOP

English

中文

Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.

Registration Number: 130349

About China Daily

Advertise on Site

Expat Employment

FOLLOW US